BioInfra Co., Ltd. (KOSDAQ:199730)
4,835.00
-120.00 (-2.42%)
At close: Jan 19, 2026
BioInfra Revenue
BioInfra had revenue of 5.07B KRW in the quarter ending September 30, 2025, a decrease of -33.50%. This brings the company's revenue in the last twelve months to 21.92B, down -16.15% year-over-year. In the year 2024, BioInfra had annual revenue of 23.83B, down -20.90%.
Revenue (ttm)
21.92B
Revenue Growth
-16.15%
P/S Ratio
1.06
Revenue / Employee
n/a
Employees
n/a
Market Cap
23.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 23.83B | -6.30B | -20.90% |
| Dec 31, 2023 | 30.13B | -5.30B | -14.96% |
| Dec 31, 2022 | 35.43B | 4.87B | 15.94% |
| Dec 31, 2021 | 30.56B | 10.95B | 55.82% |
| Dec 31, 2020 | 19.61B | 2.32B | 13.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| LabGenomics | 89.36B |
| HLB bioStep | 71.47B |
| C&R Research | 63.97B |
| DreamCIS | 62.06B |
| DT&CRO CO. | 44.36B |
| WOOJUNG BIO | 37.12B |
| P&K Skin Research Center | 22.13B |
| Curachem | 6.02B |